These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29171101)

  • 1. In vitro Inhibition of Canine Complement-Mediated Hemolysis.
    Hernandez DM; Goggs R; Behling-Kelly E
    J Vet Intern Med; 2018 Jan; 32(1):142-146. PubMed ID: 29171101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C
    Goggs R; Behling-Kelly E
    BMC Vet Res; 2019 Dec; 15(1):475. PubMed ID: 31888626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of human recombinant C1-esterase inhibitor and development of anti-drug antibodies in healthy dogs.
    Wong C; Muguiro DH; Lavergne S; Behling-Kelly E; Goggs R
    Vet Immunol Immunopathol; 2018 Sep; 203():66-72. PubMed ID: 30243377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of C1 inhibitor on tissue damage in a porcine model of controlled hemorrhage.
    Dalle Lucca JJ; Li Y; Simovic M; Pusateri AE; Falabella M; Dubick MA; Tsokos GC
    Shock; 2012 Jul; 38(1):82-91. PubMed ID: 22683724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of C1 esterase inhibitor by StcE, a metalloprotease secreted by Escherichia coli O157:H7.
    Lathem WW; Bergsbaken T; Welch RA
    J Exp Med; 2004 Apr; 199(8):1077-87. PubMed ID: 15096536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia.
    de Boer ECW; Jalink M; Delvasto-Nuñez L; Meulenbroek EM; Baas I; Janssen SR; Folman CC; Gelderman KA; Wouters D; Engel MD; de Haas M; Kersten MJ; Jongerius I; Zeerleder S; Vos JMI
    Blood Adv; 2023 Jul; 7(13):3128-3139. PubMed ID: 36920779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insight into the effects of heparinoids on complement inhibition by C1-inhibitor.
    Poppelaars F; Damman J; de Vrij EL; Burgerhof JG; Saye J; Daha MR; Leuvenink HG; Uknis ME; Seelen MA
    Clin Exp Immunol; 2016 Jun; 184(3):378-88. PubMed ID: 26874675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement factor 1 inhibitor improves cardiopulmonary function in neonatal cardiopulmonary bypass.
    Baig K; Nassar R; Craig DM; Quick G; Jiang HX; Frank MM; Lodge AJ; Anderson PA; Jaggers J
    Ann Thorac Surg; 2007 Apr; 83(4):1477-82; discussion 1483. PubMed ID: 17383361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement inhibitors to treat IgM-mediated autoimmune hemolysis.
    Wouters D; Zeerleder S
    Haematologica; 2015 Nov; 100(11):1388-95. PubMed ID: 26521297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of complement activation and effects of C1-inhibitor on the meconium-induced inflammatory reaction in human cord blood.
    Salvesen B; Nielsen EW; Harboe M; Saugstad OD; Mollnes TE
    Mol Immunol; 2009 Feb; 46(4):688-94. PubMed ID: 18950866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycosaminoglycans enhance complement hemolytic efficiency: theoretical considerations for GAG-complement-saliva interactions.
    Chang NS; Boackle RJ
    Mol Immunol; 1986 Aug; 23(8):887-93. PubMed ID: 3796630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surface-bound capsular polysaccharide of type Ia group B Streptococcus mediates C1 binding and activation of the classic complement pathway.
    Levy NJ; Kasper DL
    J Immunol; 1986 Jun; 136(11):4157-62. PubMed ID: 3517165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant C1 inhibitor in brain ischemic injury.
    Gesuete R; Storini C; Fantin A; Stravalaci M; Zanier ER; Orsini F; Vietsch H; Mannesse ML; Ziere B; Gobbi M; De Simoni MG
    Ann Neurol; 2009 Sep; 66(3):332-42. PubMed ID: 19798727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New compstatin peptides containing N-terminal extensions and non-natural amino acids exhibit potent complement inhibition and improved solubility characteristics.
    Gorham RD; Forest DL; Khoury GA; Smadbeck J; Beecher CN; Healy ED; Tamamis P; Archontis G; Larive CK; Floudas CA; Radeke MJ; Johnson LV; Morikis D
    J Med Chem; 2015 Jan; 58(2):814-26. PubMed ID: 25494040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
    Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ
    Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PASylated Coversin, a C5-Specific Complement Inhibitor with Extended Pharmacokinetics, Shows Enhanced Anti-Hemolytic Activity in Vitro.
    Kuhn N; Schmidt CQ; Schlapschy M; Skerra A
    Bioconjug Chem; 2016 Oct; 27(10):2359-2371. PubMed ID: 27598771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the complement attack mechanism in the fluid phase and its control by C567-INH: lysis of normal erythrocytes initiated by zymosan, endotoxin, and immune complexes.
    Lint TF; Behrends CL; Baker PJ; Gewurz H
    J Immunol; 1976 Nov; 117(5 Pt 1):1440-6. PubMed ID: 1002985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methods for quantitative detection of antibody-induced complement activation on red blood cells.
    Meulenbroek EM; Wouters D; Zeerleder S
    J Vis Exp; 2014 Jan; (83):e51161. PubMed ID: 24514151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study.
    Moldovan D; Reshef A; Fabiani J; Kivity S; Toubi E; Shlesinger M; Triggiani M; Montinaro V; Cillari E; Realdi G; Cancian M; Visscher S; Zanichelli A; Relan A; Cicardi M
    Clin Exp Allergy; 2012 Jun; 42(6):929-35. PubMed ID: 22909164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of compstatin family as therapeutic complement inhibitors.
    Huang Y
    Expert Opin Drug Discov; 2018 May; 13(5):435-444. PubMed ID: 29402126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.